Education
About Us
Working with TipRanks
Follow Us
Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
RESEARCH TOOLSreports
Total Valuation
Neuren Pharmaceuticals Limited has a market cap or net worth of $1.77B. The enterprise value is AU$961.25M.
Market Cap$1.77B
Enterprise ValueAU$961.25M
Share Statistics
Neuren Pharmaceuticals Limited has 126,339,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding126,339,450
Owned by Insiders0.03%
Owned by Institutions<0.01%
Financial Efficiency
Neuren Pharmaceuticals Limited’s return on equity (ROE) is 0.39 and return on invested capital (ROIC) is 37.45%.
Return on Equity (ROE)0.39
Return on Assets (ROA)0.35
Return on Invested Capital (ROIC)37.45%
Return on Capital Employed (ROCE)0.48
Revenue Per Employee26.66M
Profits Per Employee17.76M
Employee Count8
Asset Turnover0.52
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuren Pharmaceuticals Limited is 11.24. Neuren Pharmaceuticals Limited’s PEG ratio is -53.22.
PE Ratio11.24
PS Ratio0.00
PB Ratio24.08
Price to Fair Value4.39
Price to FCF279.73
Price to Operating Cash Flow278.25
PEG Ratio-53.22
Income Statement
In the last 12 months, Neuren Pharmaceuticals Limited had revenue of 213.24M and earned 142.04M in profits. Earnings per share was 1.09.
Revenue213.24M
Gross Profit213.22M
Operating Income175.55M
Pretax Income182.94M
Net Income142.04M
EBITDA175.57M
Earnings Per Share (EPS)1.09
Cash Flow
In the last 12 months, operating cash flow was -11.27M and capital expenditures -3.00K, giving a free cash flow of -11.28M billion.
Operating Cash Flow-11.27M
Free Cash Flow-11.28M
Free Cash Flow per Share-0.09
Dividends & Yields
Neuren Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.08
52-Week Price Change-28.72%
50-Day Moving Average12.10
200-Day Moving Average13.00
Relative Strength Index (RSI)59.37
Average Volume (3m)561.43K
Important Dates
Neuren Pharmaceuticals Limited upcoming earnings date is Aug 26, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateAug 26, 2025
Ex-Dividend Date―
Financial Position
Neuren Pharmaceuticals Limited as a current ratio of 8.73, with Debt / Equity ratio of 0.00%
Current Ratio8.73
Quick Ratio8.73
Debt to Market Cap0.00
Net Debt to EBITDA-0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuren Pharmaceuticals Limited has paid 40.90M in taxes.
Income Tax40.90M
Effective Tax Rate0.22
Enterprise Valuation
Neuren Pharmaceuticals Limited EV to EBITDA ratio is 9.08, with an EV/FCF ratio of -141.31.
EV to Sales7.47
EV to EBITDA9.08
EV to Free Cash Flow-141.31
EV to Operating Cash Flow-141.43
Balance Sheet
Neuren Pharmaceuticals Limited has $222.24M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -$222.24M billion.
Cash & Marketable Securities$222.24M
Total DebtAU$0.00
Net Cash-$222.24M
Net Cash Per Share-$1.76
Tangible Book Value Per Share$2.85
Margins
Gross margin is 99.93%, with operating margin of 82.32%, and net profit margin of 66.61%.
Gross Margin99.93%
Operating Margin82.32%
Pretax Margin85.79%
Net Profit Margin66.61%
EBITDA Margin82.33%
EBIT Margin82.32%
Analyst Forecast
The average price target for Neuren Pharmaceuticals Limited is $27.66, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$27.66
Price Target Upside99.00% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-8.06%
EPS Growth Forecast-10.13%